Dorothy P & Richard P Simmons Center for Interstitial Lung Disease, Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 3459 5th Avenue, Pittsburgh, PA 15261, USA.
Biomark Med. 2012 Aug;6(4):529-40. doi: 10.2217/bmm.12.38.
Idiopathic pulmonary fibrosis (IPF), the most common fibrotic lung disease, is a chronic disease of unknown etiology with a very high mortality. Personalized medicine focuses on the use of the individual's molecular and 'omic' (i.e., genomic, epigenomic and proteomic) information to direct more efficient and cost-effective strategies for prevention, diagnosis, outcome prediction and treatment of diseases. In this review, we describe the use and promise of applying 'omic' technologies to the familial and sporadic forms of IPF as a means to personalize diagnosis and outcome prediction in IPF. The validation and implementation of such approaches will be crucial to personalize IPF patient care, prioritize lung transplant and stratify patients for drug studies, as well as, in the future, predict response to therapies as they emerge.
特发性肺纤维化（IPF）是最常见的肺纤维化疾病，是一种病因不明的慢性疾病，死亡率非常高。个性化医学专注于利用个体的分子和“组学”（即基因组、表观基因组和蛋白质组学）信息，为疾病的预防、诊断、预后预测和治疗提供更有效和更具成本效益的策略。在这篇综述中，我们描述了将“组学”技术应用于家族性和散发性 IPF 的用途和前景，作为一种个性化诊断和预后预测 IPF 的方法。此类方法的验证和实施对于实现 IPF 患者护理的个性化、优先进行肺移植以及对药物研究进行分层，以及在未来预测治疗反应的出现，都将至关重要。
